Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.59
NAS:PCRX's Cash-to-Debt is ranked lower than
56% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:PCRX: 1.59 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:PCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72  Med: 1.59 Max: No Debt
Current: 1.59
Equity-to-Asset 0.56
NAS:PCRX's Equity-to-Asset is ranked lower than
58% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. NAS:PCRX: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:PCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.73  Med: 0.43 Max: 0.59
Current: 0.56
-0.73
0.59
Piotroski F-Score: 4
Altman Z-Score: 6.67
Beneish M-Score: -3.08
WACC vs ROIC
18.80%
-19.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -11.59
NAS:PCRX's Operating Margin % is ranked lower than
78% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. NAS:PCRX: -11.59 )
Ranked among companies with meaningful Operating Margin % only.
NAS:PCRX' s Operating Margin % Range Over the Past 10 Years
Min: -325.77  Med: -126.13 Max: 3.8
Current: -11.59
-325.77
3.8
Net Margin % -13.73
NAS:PCRX's Net Margin % is ranked lower than
79% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:PCRX: -13.73 )
Ranked among companies with meaningful Net Margin % only.
NAS:PCRX' s Net Margin % Range Over the Past 10 Years
Min: -300.62  Med: -133.77 Max: 0.75
Current: -13.73
-300.62
0.75
ROE % -17.15
NAS:PCRX's ROE % is ranked lower than
80% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. NAS:PCRX: -17.15 )
Ranked among companies with meaningful ROE % only.
NAS:PCRX' s ROE % Range Over the Past 10 Years
Min: -558.91  Med: -54.49 Max: 0.95
Current: -17.15
-558.91
0.95
ROA % -9.72
NAS:PCRX's ROA % is ranked lower than
78% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. NAS:PCRX: -9.72 )
Ranked among companies with meaningful ROA % only.
NAS:PCRX' s ROA % Range Over the Past 10 Years
Min: -82.83  Med: -46.36 Max: 0.52
Current: -9.72
-82.83
0.52
ROC (Joel Greenblatt) % -21.85
NAS:PCRX's ROC (Joel Greenblatt) % is ranked lower than
77% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. NAS:PCRX: -21.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:PCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -251.5  Med: -116.71 Max: 8.96
Current: -21.85
-251.5
8.96
3-Year Revenue Growth Rate 42.30
NAS:PCRX's 3-Year Revenue Growth Rate is ranked higher than
94% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. NAS:PCRX: 42.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:PCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -66.9  Med: -5.5 Max: 80.4
Current: 42.3
-66.9
80.4
3-Year EBITDA Growth Rate -34.20
NAS:PCRX's 3-Year EBITDA Growth Rate is ranked lower than
94% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. NAS:PCRX: -34.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:PCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.2  Med: -65.15 Max: -34.2
Current: -34.2
-70.2
-34.2
3-Year EPS without NRI Growth Rate -19.10
NAS:PCRX's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NAS:PCRX: -19.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:PCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -65.6 Max: -19.1
Current: -19.1
-68.6
-19.1
GuruFocus has detected 1 Warning Sign with Pacira Pharmaceuticals Inc $NAS:PCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:PCRX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PCRX Guru Trades in Q1 2016

Lee Ainslie 1,610,932 sh (New)
Ron Baron 16,211 sh (+25.44%)
Mariko Gordon 963,184 sh (+1.57%)
Ken Fisher 6,197 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2016

PCRX Guru Trades in Q2 2016

Steven Cohen 281,236 sh (New)
Jim Simons 34,800 sh (New)
Ron Baron 56,351 sh (+247.61%)
Mariko Gordon 1,076,724 sh (+11.79%)
Ken Fisher 6,197 sh (unchged)
Lee Ainslie Sold Out
» More
Q3 2016

PCRX Guru Trades in Q3 2016

Mariko Gordon 1,220,044 sh (+13.31%)
Ken Fisher 6,282 sh (+1.37%)
Steven Cohen Sold Out
Jim Simons 24,800 sh (-28.74%)
Ron Baron 21,921 sh (-61.10%)
» More
Q4 2016

PCRX Guru Trades in Q4 2016

Ron Baron 24,255 sh (+10.65%)
Jim Simons 25,200 sh (+1.61%)
Ken Fisher Sold Out
Mariko Gordon 1,219,642 sh (-0.03%)
» More
» Details

Insider Trades

Latest Guru Trades with PCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX » details
Traded in other countries:82P.Germany,
Pacira Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development, commercialization and manufacture of proprietary pharmaceutical products for use in hospitals and ambulatory surgery centers.

Pacira Pharmaceuticals Inc was incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed its name to Pacira, Inc. in June 2007. The Company is a pharmaceutical company engaged in the development, commercialization and manufacture of proprietary pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. As of December 31, 2013, its commercial stage products are EXPAREL and DepoCyt. EXPAREL is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia and was approved by the FDA on October 28, 2011. The Company commercially launched EXPAREL in April 2012. It ship EXPAREL directly to the end user based on orders placed to wholesalers or directly to the Company and have no product held by wholesalers. DepoCyt is a sustained release liposomal formulation of the chemotherapeutic agent cytarabine and is indicated for the intrathecal treatment of lymphomatous meningitis. DepoCyt was granted accelerated approval by the FDA in 1999 and full approval in 2007. The Company sells DepoCyt to its commercial partners located in the U.S. and Europe. The Company's trademarks include Pacira, EXPAREL, DepoCyt and DepoCyte. The Company's customers are AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company. Its competitors include organizations such as multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and generic drug companies. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling, release and disposal of, and exposure to, these hazardous materials. In addition to regulations in the United States, it is subject to various foreign regulations governing clinical trials and the commercial sales and distribution of its products.

Guru Investment Theses on Pacira Pharmaceuticals Inc

Baron Funds Comments on PaciraPharmaceuticals - Jan 18, 2017

Other companies we favor have wrapped intellectual property around an already proven pharmaceutical to create a new, protected franchise. The risk of not receiving approval for such products is significantly lower than for a typical bio-pharma investment. An example is PaciraPharmaceuticals, Inc. (NASDAQ:PCRX), whose FDA-approved medication is comprised of the pain killer bupivacaine combined with proprietary IP called Depo-Foam that enables its timed release. The product is appealing as it can in many cases eliminate the need for post-operative opiates and result in a shorter hospital stay.



From Baron Discovery Fund's Investing in Earlier Stage Small Cap Growth Companies January 2017.



Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals - Aug 10, 2016

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells an injectable drug for local post-surgical analgesia (localized pain relief) called EXPAREL. In the fourth quarter of 2015, Pacira reached a very favorable resolution with the FDA concerning certain issues which had previously impeded its ability to market its drug to hospital customers. We re-established our investment in the company in the third quarter of 2015 as it appeared from public reports that the company was making significant progress on this front (and the FDA removed the warning letter from its site in September). Shares have been weak in the second quarter of 2016 as Pacira has not yet seen a re-acceleration in the growth of the drug (management has always guided to a late 2016 effect). In our opinion, Pacira still retains its large multi-billion dollar market opportunity, and we should start to see accelerating revenues by year-end.



From Baron Discovery Fund's second quarter 2016 commentary.





Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals Inc. - May 19, 2016

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a drug for local surgical analgesia (an anesthetic) called EXPAREL. At the end of the third quarter of 2015, Pacira received a favorable resolution of certain FDA issues, and we re-established our investment at the lower levels caused by the prior regulatory uncertainty. In our opinion, shares were down in the first quarter due to the general negative industry dynamics around pharmaceutical companies.



From the Baron Global Advantage Fund first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals Inc. - Feb 25, 2016

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a long-lasting pain medication called EXPAREL. This is an approved drug for local surgical analgesia (an anesthetic) that can be used for a multitude of soft tissue and orthopedic procedures. Ultimately, we believe that Pacira will obtain a nerve block indication for the drug as well. Effectively, Pacira has taken a generic drug called bupivacaine (under use for decades) and wrapped it with a special time release coating that allows analgesic effects to last for up to three days instead of just hours. This saves money for the health care system by allowing for earlier release of patients and much lower use of dangerous opioid pain killers. This wrapper technology can be used for other drugs, and the company is developing a number of these which could bring additional upside to valuation. We were prior owners of Pacira, but sold the investment at much higher levels when we grew concerned about regulatory issues with the FDA that cropped up at the end of 2014. Shares dropped considerable after that. By the end of the third quarter, we anticipated a favorable resolution of these issues after the FDA removed the warning letter from its website (a highly unusual event), and we re-established our investment at the lower levels caused by the regulatory uncertainty. In the fourth quarter, Pacira resolved all of its marketing issues with the FDA via a formal agreement. This could allow for accelerated growth in 2016. Run rate sales of EXPAREL are now about $250 million and the market could be worth billions. Pacira has the potential for years of continued growth.



From Baron Discover Fund's fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Pacira Pharmaceuticals Inc

Baron Funds Comments on PaciraPharmaceuticals Guru stock highlight
Other companies we favor have wrapped intellectual property around an already proven pharmaceutical to create a new, protected franchise. The risk of not receiving approval for such products is significantly lower than for a typical bio-pharma investment. An example is PaciraPharmaceuticals, Inc. (NASDAQ:PCRX), whose FDA-approved medication is comprised of the pain killer bupivacaine combined with proprietary IP called Depo-Foam that enables its timed release. The product is appealing as it can in many cases eliminate the need for post-operative opiates and result in a shorter hospital stay. Read more...
Baron Funds Comments on Pacira Pharmaceuticals Guru stock highlight
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells an injectable drug for local post-surgical analgesia (localized pain relief) called EXPAREL. In the fourth quarter of 2015, Pacira reached a very favorable resolution with the FDA concerning certain issues which had previously impeded its ability to market its drug to hospital customers. We re-established our investment in the company in the third quarter of 2015 as it appeared from public reports that the company was making significant progress on this front (and the FDA removed the warning letter from its site in September). Shares have been weak in the second quarter of 2016 as Pacira has not yet seen a re-acceleration in the growth of the drug (management has always guided to a late 2016 effect). In our opinion, Pacira still retains its large multi-billion dollar market opportunity, and we should start to see accelerating revenues by year-end. Read more...
Baron Funds Comments on Pacira Pharmaceuticals Inc. Guru stock highlight
Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a drug for local surgical analgesia (an anesthetic) called EXPAREL. At the end of the third quarter of 2015, Pacira received a favorable resolution of certain FDA issues, and we re-established our investment at the lower levels caused by the prior regulatory uncertainty. In our opinion, shares were down in the first quarter due to the general negative industry dynamics around pharmaceutical companies. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 111.11
PCRX's Forward PE Ratio is ranked lower than
99% of the 109 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.08 vs. PCRX: 111.11 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 8.16
PCRX's PB Ratio is ranked lower than
87% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. PCRX: 8.16 )
Ranked among companies with meaningful PB Ratio only.
PCRX' s PB Ratio Range Over the Past 10 Years
Min: 3.47  Med: 10.1 Max: 73.42
Current: 8.16
3.47
73.42
PS Ratio 6.39
PCRX's PS Ratio is ranked lower than
75% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. PCRX: 6.39 )
Ranked among companies with meaningful PS Ratio only.
PCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.39  Med: 12.11 Max: 30.31
Current: 6.39
0.39
30.31
Price-to-Free-Cash-Flow 203.80
PCRX's Price-to-Free-Cash-Flow is ranked lower than
91% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.25 vs. PCRX: 203.80 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PCRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 130.39  Med: 438.65 Max: 1333.3
Current: 203.8
130.39
1333.3
Price-to-Operating-Cash-Flow 52.66
PCRX's Price-to-Operating-Cash-Flow is ranked lower than
84% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.28 vs. PCRX: 52.66 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PCRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.69  Med: 84.13 Max: 909.74
Current: 52.66
33.69
909.74
Current Ratio 5.42
PCRX's Current Ratio is ranked higher than
80% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. PCRX: 5.42 )
Ranked among companies with meaningful Current Ratio only.
PCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.69 Max: 5.42
Current: 5.42
0.87
5.42
Quick Ratio 4.72
PCRX's Quick Ratio is ranked higher than
79% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. PCRX: 4.72 )
Ranked among companies with meaningful Quick Ratio only.
PCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.32 Max: 4.72
Current: 4.72
0.75
4.72
Days Inventory 169.11
PCRX's Days Inventory is ranked lower than
74% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. PCRX: 169.11 )
Ranked among companies with meaningful Days Inventory only.
PCRX' s Days Inventory Range Over the Past 10 Years
Min: 31.07  Med: 75.65 Max: 230.95
Current: 169.11
31.07
230.95
Days Sales Outstanding 39.54
PCRX's Days Sales Outstanding is ranked higher than
82% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. PCRX: 39.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
PCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.85  Med: 40.64 Max: 67.76
Current: 39.54
29.85
67.76
Days Payable 24.90
PCRX's Days Payable is ranked lower than
89% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. PCRX: 24.90 )
Ranked among companies with meaningful Days Payable only.
PCRX' s Days Payable Range Over the Past 10 Years
Min: 20.45  Med: 44.4 Max: 246.51
Current: 24.9
20.45
246.51

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.70
PCRX's 3-Year Average Share Buyback Ratio is ranked higher than
51% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. PCRX: -3.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -288.4  Med: -138 Max: -3.7
Current: -3.7
-288.4
-3.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 24.95
PCRX's Price-to-Net-Current-Asset-Value is ranked lower than
84% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. PCRX: 24.95 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PCRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 12.54  Med: 33.98 Max: 54.06
Current: 24.95
12.54
54.06
Price-to-Tangible-Book 10.20
PCRX's Price-to-Tangible-Book is ranked lower than
83% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. PCRX: 10.20 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.1  Med: 12.8 Max: 64.96
Current: 10.2
5.1
64.96
Price-to-Median-PS-Value 0.52
PCRX's Price-to-Median-PS-Value is ranked higher than
92% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. PCRX: 0.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.05 Max: 1.8
Current: 0.52
0.35
1.8
Earnings Yield (Greenblatt) % -1.69
PCRX's Earnings Yield (Greenblatt) % is ranked lower than
72% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. PCRX: -1.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.7  Med: 0.4 Max: 1.2
Current: -1.69
-1.7
1.2

More Statistics

Revenue (TTM) (Mil) $276.4
EPS (TTM) $ -1.01
Beta2.25
Short Percentage of Float18.28%
52-Week Range $29.95 - 65.64
Shares Outstanding (Mil)39.93

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 314 425 553
EPS ($) 0.36 2.03 3.96
EPS without NRI ($) 0.36 2.03 3.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
36.00%
Dividends per Share ($)
» More Articles for PCRX

Headlines

Articles On GuruFocus.com
4 Biotech Stocks to Watch Mar 22 2017 
Baron Funds Comments on PaciraPharmaceuticals Jan 18 2017 
Investing in Earlier Stage Small Cap Growth Companies - Baron Discovery Fund Jan 18 2017 
Baron Funds Comments on Pacira Pharmaceuticals Aug 10 2016 
Baron Funds Comments on Pacira Pharmaceuticals Inc. May 19 2016 
Baron Funds Comments on Pacira Pharmaceuticals Inc. Feb 25 2016 
Mariko Gordon Nearly Doubles Stake in Forward Air Jan 04 2016 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Mariko Gordon's First Quarter Top Five May 15 2014 
Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 

More From Other Websites
Anesthesia Can't Save This Biotech From Feeling Pain: Analyst Mar 23 2017
4 Biotech Stocks to Watch Mar 22 2017
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide Mar 16 2017
Pacira Pharmaceuticals stock rises 2% on positive late-stage trial for opioid-reducing pain... Mar 14 2017
Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption... Mar 14 2017
PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 13 2017
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Mar 13 2017
PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 08 2017
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375%... Mar 07 2017
PACIRA PHARMACEUTICALS, INC. Financials Mar 07 2017
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of... Mar 06 2017
ETFs with exposure to Pacira Pharmaceuticals, Inc. : March 6, 2017 Mar 06 2017
Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy Mar 06 2017
Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential Mar 03 2017
Pacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
Pacira Spikes on Earnings Beat, Positive Results (PCRX) Mar 02 2017
4 Biopharma Stocks Moving the Market on Wednesday Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)